WO2000027376A3 - Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus - Google Patents

Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus Download PDF

Info

Publication number
WO2000027376A3
WO2000027376A3 PCT/EP1999/008071 EP9908071W WO0027376A3 WO 2000027376 A3 WO2000027376 A3 WO 2000027376A3 EP 9908071 W EP9908071 W EP 9908071W WO 0027376 A3 WO0027376 A3 WO 0027376A3
Authority
WO
WIPO (PCT)
Prior art keywords
tinnitus
oxidoreductases
hydrolases
treatment
thiol compounds
Prior art date
Application number
PCT/EP1999/008071
Other languages
English (en)
French (fr)
Other versions
WO2000027376A2 (de
Inventor
Michael Schedler
Albert Lind
Original Assignee
Michael Schedler
Albert Lind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19856210A external-priority patent/DE19856210A1/de
Application filed by Michael Schedler, Albert Lind filed Critical Michael Schedler
Publication of WO2000027376A2 publication Critical patent/WO2000027376A2/de
Publication of WO2000027376A3 publication Critical patent/WO2000027376A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft die Verwendung von Thiolverbindungen, Oxidoreduktasen und/oder Hydrolasen zur Behandlung des Tinnitus, insbesondere des chronischen Tinnitus, aber auch des Innenohrschwindels.
PCT/EP1999/008071 1998-10-26 1999-10-26 Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus WO2000027376A2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19849290 1998-10-26
DE19849290.1 1998-10-26
DE19856210.1 1998-12-06
DE19856210A DE19856210A1 (de) 1998-10-26 1998-12-06 Verwendung von Thiolverbindungen, Oxidoreduktasen und/oder Hydrolasen zur Behandlung des Tinnitus, insbesondere des chronischen Tinnitus

Publications (2)

Publication Number Publication Date
WO2000027376A2 WO2000027376A2 (de) 2000-05-18
WO2000027376A3 true WO2000027376A3 (de) 2000-09-14

Family

ID=26049761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/008071 WO2000027376A2 (de) 1998-10-26 1999-10-26 Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus

Country Status (1)

Country Link
WO (1) WO2000027376A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
EP1712220A1 (de) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmazeutische Aerosolzusammensetzung
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014456A1 (en) * 1991-02-22 1992-09-03 Shapiro Howard K Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0609701A1 (de) * 1993-01-27 1994-08-10 Ajinomoto Co., Inc. L-Cystein, L-Cystin oder L-Glutamin als zusätzliches Arzneimittel zur Behandlung des Immundefizienssyndroms
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014456A1 (en) * 1991-02-22 1992-09-03 Shapiro Howard K Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
EP0609701A1 (de) * 1993-01-27 1994-08-10 Ajinomoto Co., Inc. L-Cystein, L-Cystin oder L-Glutamin als zusätzliches Arzneimittel zur Behandlung des Immundefizienssyndroms
WO1995001096A1 (en) * 1993-06-29 1995-01-12 Shapiro Howard K Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology

Also Published As

Publication number Publication date
WO2000027376A2 (de) 2000-05-18

Similar Documents

Publication Publication Date Title
MXPA03007816A (es) Calzoncillo desechable y metodo para proporcionar el mismo.
HK1038693A1 (zh) 治療眼、耳、鼻病症的抗生素合成劑
DK1459749T3 (da) (S,S)-reboxetin til behandling af inkontinens
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
WO2001044247A3 (en) Agents and methods for the treatment of proliferative diseases
YU89503A (sh) Korišćenje osteopontina za lečenje i/ili prevenciju neuroloških bolesti
ZA200007642B (en) Treatment of airborne microorganisms.
MXPA03007690A (es) Prenda absorbente y metodo para proporcionar la misma.
ZA200501288B (en) Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma.
HK1038694A1 (zh) 治療眼、耳、鼻病症的抗生素合成劑
HK1038692A1 (zh) 治療眼、耳、鼻病症的抗生素合成劑
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
HK1064261A1 (en) Method for the treatment of tobacco.
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
EP0681787A3 (de) Verwendung eines Enzyms zur Herstellung eines Mittels für die Behandlung und/oder Prophylaxe von Coccidiose.
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
WO2000027376A3 (de) Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus
ZA200004363B (en) Treatment or prevention of coccidiosis.
AU2001280093A1 (en) Method for the prevention and treatment of retinopathy
WO2001044235A3 (en) Agents and methods for the treatment of proliferative diseases
AP2005003272A0 (en) S-Methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorder.
IL143280A0 (en) Use of riluzole for treating acoustic traumas

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase